Considering the immunological benefits of decitabine (DAC) observed in enhancing CD19 CAR T cell activity against B-ALL and NHL, we have included DAC in the lymphodepletion regimen for adult patients with B cell neoplasms undergoing CD19 CAR T cell therapy.11 Here, CD19 is linked to B-cell neoplasm.